Search
Products meeting the search criteria
Adarbi 40 mg Tablet, 1 Strip
Adarbi 40 mg Tablet, 1 StripDescription:Adarbi (Azilsartan Medoxomil), a prodrug, is hydrolyzed to Azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.IndicationAdarbi (Azilsartan Medoxomil) is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarction. Adarbi (Azilsartan Medoxomil) may be used either alone or in combination with other antihypertensive agents.Dosage & AdministrationThe recommended dose in adults is 80 mg taken orally once daily. Consider a Starting dose of 40 mg for patients who are treated with high doses of diuretics. If blood pressure is not controlled with Adarbi alone, additional blood pressure reduction can be ahieved by taking Edarbi with other antihypertensive agents.ContraindicationIt is contraindicated to co-administer Aliskiren with Azilsartan in patients with Diabetes.PrecautionUse of Azilsartan Medoxomil during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. In patients who are intravascularly volume-depleted (e.g., those treated with high-dose diuretics), symptomatic hypotension may occur. Changes in renal function including renal failure has been reported in renal impaired patient.Side EffectsThe most common adverse reaction in adults is diarrhea. The other side effects are nausea, asthenia, fatigue, muscle spasm, dizziness and cough.Drug InteractionNo drug interactions have been observed in studies of Azilsartan Medoxomil or Azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone and warfarin. The antihypertensive effect of Azilsartan may be attenuated by the non-steroidal anti-inflammatory drugs including selective COX-2 inhibitors. Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors or aliskiren is associated with increased risks of hypotension, hyperkalemia and changes in renal function.Storage Conditionkeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.120.00/=
Altrip 6.25 mg Tablet, 1 strip
Altrip 6.25 mg Tablet, 1 stripDescription:Almotriptan is a selective and potent serotonin (5-HT1B/1D) agonist. Almotriptan binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.ndicationAlmotriptan is prescribed to treat the acute headache phase of migraine attacks with or without aura. Almotriptan is the only oral triptan approved in the USA for the treatment of migraine in adolescent from 12 to 17 years of age.Dosage & AdministrationAcute Treatment of Migraine Attacks: The recommended dose of Altrip in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial Altrip (almotriptan malate) dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.Hepatic Impairment:The recommended starting dose of almotriptan malate in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodRenal Impairment:The recommended starting dose of almotriptan malate in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodContraindicationAs with other 5-HT1B/1D receptor agonists, almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetals angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.PrecautionHypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular diseaseSide EffectsSerious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD (Coronary Artery Disease).Drug InteractionThese drugs have been reported to cause prolonged vasospastic reactions. Cases of life-threatening serotonin syndrome have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).OverdoseNo case of overdose has been reported. The most frequently reported adverse event in patients receiving 150 mg (the highest dose administered to patients) was somnolence.Pregnancy & LactationPregnancy Category C. There is no data regarding excretion of almotriptan in human milk.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.250.80/=
Anxionil 3 mg Tablet, 1 strip
Anxionil 3 mg Tablet, 1 stripDescription:Anxionil is a preparation of Bromazepam. Bromazepam is a powerful psychotropic agent. In lower dosage, it selectively reduces tension and anxiety. In higher dosage, it shows sedative and muscle-relaxant properties.IndicationEmotional disturbances, i.e. acute tension and anxiety states. Difficulties in interpersonal contact. Agitation, insomnia, anxious and agitated depressive reactions.Functional disturbances in the cardiovascular and respiratory systems, i.e. pseudoangina pectoris, pericardial anxiety, tachycardia, emotiogenic hypertension, dyspnea and hyperventilation.Disturbances in the gastrointestinal tract, i.e. irritable bowel syndrome, epigastric pain, spasm, bloating diarrhea etc.Disturbances in the urinary tract, i.e. frequency, irritable bladder and dysmenorrhea. Psychosomatic disorder, i.e. psychogenic headache, asthma, gastric and duodenal ulcer. It is also indicated in emotional reactions to chronic organic disease.Dosage & AdministrationStandard dosage : Average dosage for outpatient therapy is 1.5-3 mg up to three times daily. Treatment of outpatients should begin with low doses, gradually increasing to the optimum level. In severe cases, especially in hospital, 6 -12 mg 2 or 3 times daily. The overall treatment generally should not be more than 8-12 weeks. In certain cases extension beyond the maximum treatment period may be necessary; if so, it should be taken with re-evaluation of the patients status with special expertise.Elderly and debilitated patients : Elderly patients and those with impaired hepatic functions require lower doses.Children : Bromazepam is usually not indicated in children, but if the physician feels bromazepam treatment is appropriate, then the dose should be adjusted to their low bodyweight (about 0.1-0.3 mg/kg bodyweight)ContraindicationBromazepam is contraindicated in patients with known hypersensitivity to bromazepam, severe respiratory insufficiency, severe hepatic insufficiency or sleep apnea syndromPrecautionThe use of benzodiazepines and benzodiazepine like agents may lead to the development of physical and psychological dependence upon these products. This dependence depends on the dose and duration of treatment; it is also greater in predisposed patients with a history of alcohol. Once physical dependence has developed, termination of the treatment will be accompanied by withdrawal symptoms. These may consist of headache, muscle pain, extreme anxiety, tension, confusion and irritability. Since the risk of withdrawal phenomena and rebound phenomena is greater after abrupt discontinuation of the treatment, it is recommended that the dosage be decreased gradually. Bromazepam is not recommended for the primary treatment of sleeplessness caused by psychotic illness. Caution should be exercised while driving cars or using machineries.Side EffectsCommon side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. These phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. Anterograde amnesia may occur using therapeutic dosDrug InteractionIf bromazepam is combined with other centrally active drugs, its sedative effects may be enhanced. These drugs are antidepressants, hypnotics, narcotics, antipsychotics, sedatives, antiepileptic drugs, sedative antihistamines and anesthetics. Co-administration of cimetidine may prolong the eliminiation half-life of bromazepam. Concomitant intake of bromazepam with alcohol should be avoided, because the sedative effect of bromazepam may be intensified by alcoPregnancy & LactationThe safety of bromazepam during pregnancy has not been established. As bromazepam is excreted in breast milk, use should be avoided during lactatioStorage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.50.20/=
Doxiva 200 mg Tab, 1 strip
Doxiva 200 mg Tab, 1 stripDescription:Doxiva (Doxophylline) is a novel bronchodilator. It structurally differs from Theophylline due to the presence of a dioxolane group in position 7. Doxophylline selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth muscle. However, differently from Theophylline, Doxophylline appears to have decreased affinities toward adenosine A1 and A2 receptors, which may account for the better safety profile of the drug. Doxophylline is reported to inhibit platelet activating factor (PAF) and generation of leukotriene production.IndicationDoxiva (Doxophylline) is used to treat asthma, COPD and bronchospasm.Dosage & AdministrationAdults : 1 tablet daily in the evening. On the basis of clinical response the dose may be increased to 1 tablet twice daily.Children (above 6 years of age) : 6 mg/kg twice daily.ContraindicationDoxophylline is contraindicated in acute myocardial infarction. It is also contraindicated in patients with hypotension, in lactating women & patients who have shown hypersensitivity to its componentsPrecautionThe half-life of xanthine derivatives is influenced by a number of known variables. It may be prolonged in patients with liver disease, in patients with congestive heart failure and in those patients taking certain other drugs like erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, propanolol and anti-flu vaccine. In these cases, a lower dose of Doxophylline may be needed. Phenytoin, other anticonvulsants and smoking may cause an increase in clearance with a shorter mean half-life. In these cases higher doses of Doxophylline may be needed.Side EffectsDoxophylline rarely causes serious side effects, however possible side effect are similar for taking excess amount of caffeine. These include: nausea, vomiting, headaches, upset stomach and heartburn.Drug InteractionDoxiva (Doxophylline) is used to treat asthma, COPD and bronchospasm.Pregnancy & LactationAnimal reproduction studies indicate that, Doxophylline does not cause fetal harm when administered to pregnant animals or can not affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to pregnant women only if clearly needed. Doxophylline is contraindicated in nursing mothers.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.60.00/=
Doxiva 400 mg Tab, 1 strip
Doxiva 400 mg Tab, 1 stripDescription:Doxiva (Doxophylline) is a novel bronchodilator. It structurally differs from Theophylline due to the presence of a dioxolane group in position 7. Doxophylline selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth muscle. However, differently from Theophylline, Doxophylline appears to have decreased affinities toward adenosine A1 and A2 receptors, which may account for the better safety profile of the drug. Doxophylline is reported to inhibit platelet activating factor (PAF) and generation of leukotriene production.IndicationDoxiva (Doxophylline) is used to treat asthma, COPD and bronchospasm.Dosage & AdministrationAdults : 1 tablet daily in the evening. On the basis of clinical response the dose may be increased to 1 tablet twice daily.Children (above 6 years of age) : 6 mg/kg twice daily.ContraindicationDoxophylline is contraindicated in acute myocardial infarction. It is also contraindicated in patients with hypotension, in lactating women & patients who have shown hypersensitivity to its componentsPrecautionThe half-life of xanthine derivatives is influenced by a number of known variables. It may be prolonged in patients with liver disease, in patients with congestive heart failure and in those patients taking certain other drugs like erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, propanolol and anti-flu vaccine. In these cases, a lower dose of Doxophylline may be needed. Phenytoin, other anticonvulsants and smoking may cause an increase in clearance with a shorter mean half-life. In these cases higher doses of Doxophylline may be needed.Side EffectsDoxophylline rarely causes serious side effects, however possible side effect are similar for taking excess amount of caffeine. These include: nausea, vomiting, headaches, upset stomach and heartburn.Drug InteractionDoxiva (Doxophylline) is used to treat asthma, COPD and bronchospasm.Pregnancy & LactationAnimal reproduction studies indicate that, Doxophylline does not cause fetal harm when administered to pregnant animals or can not affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to pregnant women only if clearly needed. Doxophylline is contraindicated in nursing mothers.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.100.00/=
Flexivan ER Tablet 200 mg, 1 strip
Flexivan ER Tablet 200 mg, 1 stripDescription:Flexivan ER (Aceclofenac) is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.CompositionEach extended release tablet contains Aceclofenac BP 200 mg.IndicationAceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma and lumbago.Dosage & AdministrationThe recommended dose in adults is one tablet (Flexivan ER 200 mg) daily or as prescribed by the physician.ContraindicationAceclofenac is contraindicated in patients with known hypersensitivity to it or in whom aspirin or NSAIDs precipitate attacks of asthma.PrecautionCaution should be exercised to patients with active or suspected peptic ulcer or gastro-intestinal bleeding moderate to severe hepatic impairment and cardiac or renal impairment. Caution should also be exercised in patients suffering from dizziness or urticaria.Side EffectsMajority of side effects are minor in nature and reversible. These are dyspepsia, abdominal pain, nausea, rash and urticaria.Drug InteractionNo significant drug interactions has not been observed but close monitoring of patients is required when it is used with lithium and digoxin, oral antidiabetic agents, anticoagulants, diuretics and other analgesics.Pregnancy & LactationThe use of Aceclofenac should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.Storage Conditionkeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.60.20/=
Lijenta 5 Tab, 1 strip
Lijenta 5 Tab, 1 stripDescription:Lijenta 5 is an inhibitor of DPP-4 , an enzyme that degrades the incretin hormones GLP-1 and GIP. Thus, Linagliptin increases the concentratins of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucangon from pancreatic alpha cells in the circulation.Thus it improves glycemic control in patients with type 2 diabetes mellitus.IndicationLijenta 5 is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults. As monotherapy-in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment. As combination therapy-in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control-in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Dosage & Administration5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulfonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.Patients with renal impairment: no dose adjustment required. Linagliptin can be taken with or without a meal at any time of the day.ContraindicationHypersensitivity to the active substance or to any of the excipients.PrecautionLinagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.Side EffectsThere may be hypoglycaemia, nasopharyngitis, cough and pancreatitis in combination with metformin and sulfonylurea.Drug InteractionLinagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives.Pregnancy & LactationAvoid use during pregnancy. A risk to the breast-fed child cannot be excluded.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.330.00/=
Lijenta-M 500 Tab, 1 strip
Lijenta-M 500 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.120.00/=
Lijenta-M 850 Tab, 1 strip
Lijenta-M 850 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.112.00/=
Lipidof 200 mg Capsule, 1 strip
Lipidof 200 mg Capsule, 1 stripDESCRIPTIONLIPIDOF 200 (Fenofibrate) is a lipid-regulating agent. Fenofibric acid, the active metabolite of Fenofibrate, lowers plasma triglycerides apparently by inhibiting triglyceride synthesis, resulting in a reduction ofVLDL released into the circulation, and also by stimulating the catabolism of triglyceride rich lipoprotein (i.e. VLDL). Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.COMPOSITIONLIPIDOF 200: Each capsule contains micronized Fenofibrate BP 200 mg.INDICATIONSLIPIDOF 200 (Fenofibrate) is indicated as adjunctive therapy to diet for the treatment of hypertriglyceridemia (Fredrickson Types IV and V) and also for primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa, IIb) who are at risk of pancreatitis and who do not respond adequately to dietary effort.DOSAGE AND ADMINISTRATIONPatients should be placed on an appropriate lipid lowering diet before receiving Fenofibrate, and should continue this diet during treatment with it. It should be taken with meal for better absorption.The recommended dose of LIPIDOF 200 mg capsule is once daily for the treatment of primary hypercholesterolemia, hypertriglyceridemia, or mixed hyperlipidemia.OR AS DIRECTED BY THE PHYSICIAN.SIDE EFFECTSThe most common side effects of Fenofibrate therapy are gastrointestinal upsets including nausea, anorexia, and gastric disorder. Other adverse effects reported to occur less frequently include pruritus, urticaria, headache, dizziness, vertigo, fatigue, hair loss, myotoxicity (with myasthenia or myalgia), skin rash, anemia, leucopenia, and thrombo-cytopenia.CONTRAINDICATIONSFenofibrate is contraindicated in patients who exhibit hypersensitivity to it. Fenofibrate is also contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, and patients with unexplained persistent liver function abnormality. It is also contraindicated in patients with preexisting gall bladder disease.PRECAUTIONSDuring Fenofibrate therapy monitoring of liver function tests in every 3 months for first year should be performed and therapy should be discontinued if enzyme levels persist above three times the normal limit.Use in pregnancy & lactationPregnancy : Fenofibrate is not recommended for pregnant women.Lactation : Fenofibrate should not be used in lactating mothers.USE IN CHILDRENSafety and effectiveness in children have not been established.DRUG INTERACTIONSAnticoagulant: Fenofibrate may enhance the effects of oral anticoagulants; thus the dose of anticoagulants should be reduced to maintain the Prothrombin Time at the desired level to prevent bleeding complications when treatment with Fenofibrate is started, and then adjusted gradually if necessary.Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Fenofibrate, there is a risk that an interaction will lead to deterioration.OVERDOSAGEThere is no specific treatment for overdose with Fenofibrate. General supportive care of the patients is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur.Because Fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.SUPPLYLIPIDOF 200 : Each box contains 2 X 10 capsules in blisters.strips...
Tk.70.40/=
Lovapres 5mg Tablet, 1 Strip
Lovapres 5mg Tablet, 1 StripDescription:Lovapres(Amlodipine) is a long-acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Thus it causes reduction in peripheral vascular resistance and contractile process in cardiac muscle and reduces blood pressure.IndicationLovapres(Amlodipine) is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of Hypertension and Coronary Artery Disease (such as Chronic Stable Angina, Vasospastic Angina and Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%) .Dosage & AdministrationAdult: Starting dose 5 mg once daily with maximum dose 10 mg once daily. Small, Fragile and Elderly patients or patients with hepatic insufficiency: Starting dose 2.5 mg once daily.Pediatric: Starting dose 2.5 mg to 5 mg once daily.ContraindicationIt is contraindicated in patients with known sensitivity to AmlodipinePrecautionSymptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, because of the gradual onset of action, acute hypotension is unlikely. Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of Amlodipine, particularly in patients with severe obstructive coronary artery disease. Titrate slowly when administering calcium channel blockers to patients with severe hepatic impairment.Side EffectsMost common side effects are headache and edema which occurred in a dose related manner. Other side effects not dose related but reported with an incidence >1.0% are headache, fatigue, nausea, abdominal pain and somnolence.Drug InteractionAmlodipine has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerine, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. Amlodipine has no effect on protein binding of digoxin, phenytoin, warfarin, or indomethacin. Administration of Amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.Pregnancy & LactationPregnancy Category C. There are no adequate and well-controlled studies of Amlodipine in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while Amlodipine is administered.Storage Conditionkeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.50.00/=
Metavas MR 35 mg Tablet, 1 Strip
Metavas MR 35 mg Tablet, 1 StripDescription:Metavas MR (Trimetazidine Dihydrochloride) is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Metavas MR (Trimetazidine) inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.CompositionEach modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.IndicationMetavas MR (Trimetazidine Dihydrochloride) is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.Dosage & AdministrationThe recommended dose of Trimetazidine is 35 mg twice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.ContraindicationTrimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson disease, parkinsonian symptoms, tremors, restlessleg movement disorders, severe renal impairment.PrecautionTrimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is not a treatment for myocardial infarction.Side EffectsTrimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and astheniaDrug InteractionNo drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.Pregnancy & LactationThere are no data from the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.60.00/=
Montiva 10 Tablet, 1 strip
Montiva 10 Tablet, 1 stripDescription:Montelukast is a selective and orally active competitive cysteinyl leukotriene receptor antagonist, that inhibits the cysteinyl leukotriene (CysLT1) receptor to occupy the receptor. The cysteinyl leukotriene (CysLT1) receptor is found in the human airway with which cysteinyl leukotrienes bind to cause edema and smooth muscle contraction. Cysteinyl leukotrienes (CysLTs) have been correlated with the pathophysiology of asthma and allergic rhinitis.IndicationMontelukast is indicated for the prophylaxis and chronic treatment of asthma, exercise-induced bronchoconstriction (EIB) and seasonal allergic rhinitis.Dosage & AdministrationFor adults and adolescents (15 years of age and older): 10 mg tablet once daily in the evening.Children 6-14 years: 5 mg Oroflash tablet once daily in the evening.ContraindicationMontelukast is contraindicated to patients with hypersensitivity to any component of this product.PrecautionMontelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Montelukast should not be abruptly substituted for inhaled or oral corticosteroids. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Montelukast. Patients should be alert for neuropsychiatric events. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications presenting in their patients.Side EffectsGenerally, Montelukast is well-tolerated. Side effects include fever, headache, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, upper respiratory tract infection.Drug InteractionMontelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medical products: theophylline, prednisolone, prednisone, oral contraceptives, terfenadine, digoxin and warfarin.Pregnancy & LactationIn Pregnancy: Montelukast is a pregnancy category B drug .There is no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.In Lactation: It is not known if Montelukast is excreted in human milk. Caution should be exercised when Montelukast is given to a nursing mother.Storage ConditionKeep in dry place away from light and heat. Keep out of the reach of children...
Tk.150.00/=
Montiva 4 mg Tablet, 1 strip
Montiva 4 mg Tablet, 1 stripDescription:Montelukast is a selective and orally active competitive cysteinyl leukotriene receptor antagonist, that inhibits the cysteinyl leukotriene (CysLT1) receptor to occupy the receptor. The cysteinyl leukotriene (CysLT1) receptor is found in the human airway with which cysteinyl leukotrienes bind to cause edema and smooth muscle contraction. Cysteinyl leukotrienes (CysLTs) have been correlated with the pathophysiology of asthma and allergic rhinitis.IndicationMontelukast is indicated for the prophylaxis and chronic treatment of asthma, exercise-induced bronchoconstriction (EIB) and seasonal allergic rhinitis.Dosage & AdministrationFor adults and adolescents (15 years of age and older): 10 mg tablet once daily in the evening.Children 6-14 years: 5 mg Oroflash tablet once daily in the evening.ContraindicationMontelukast is contraindicated to patients with hypersensitivity to any component of this product.PrecautionMontelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Montelukast should not be abruptly substituted for inhaled or oral corticosteroids. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Montelukast. Patients should be alert for neuropsychiatric events. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications presenting in their patients.Side EffectsGenerally, Montelukast is well-tolerated. Side effects include fever, headache, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, upper respiratory tract infection.Drug InteractionMontelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medical products: theophylline, prednisolone, prednisone, oral contraceptives, terfenadine, digoxin and warfarin.Pregnancy & LactationIn Pregnancy: Montelukast is a pregnancy category B drug .There is no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.In Lactation: It is not known if Montelukast is excreted in human milk. Caution should be exercised when Montelukast is given to a nursing mother.Storage ConditionKeep in dry place away from light and heat. Keep out of the reach of children...
Tk.60.00/=
Montiva 5 mg Tablet, 1 strip
Montiva 5 mg Tablet, 1 stripDescription:Montelukast is a selective and orally active competitive cysteinyl leukotriene receptor antagonist, that inhibits the cysteinyl leukotriene (CysLT1) receptor to occupy the receptor. The cysteinyl leukotriene (CysLT1) receptor is found in the human airway with which cysteinyl leukotrienes bind to cause edema and smooth muscle contraction. Cysteinyl leukotrienes (CysLTs) have been correlated with the pathophysiology of asthma and allergic rhinitis.IndicationMontelukast is indicated for the prophylaxis and chronic treatment of asthma, exercise-induced bronchoconstriction (EIB) and seasonal allergic rhinitis.Dosage & AdministrationFor adults and adolescents (15 years of age and older): 10 mg tablet once daily in the evening.Children 6-14 years: 5 mg Oroflash tablet once daily in the evening.ContraindicationMontelukast is contraindicated to patients with hypersensitivity to any component of this product.PrecautionMontelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Montelukast should not be abruptly substituted for inhaled or oral corticosteroids. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Montelukast. Patients should be alert for neuropsychiatric events. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications presenting in their patients.Side EffectsGenerally, Montelukast is well-tolerated. Side effects include fever, headache, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, upper respiratory tract infection.Drug InteractionMontelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medical products: theophylline, prednisolone, prednisone, oral contraceptives, terfenadine, digoxin and warfarin.Pregnancy & LactationIn Pregnancy: Montelukast is a pregnancy category B drug .There is no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.In Lactation: It is not known if Montelukast is excreted in human milk. Caution should be exercised when Montelukast is given to a nursing mother.Storage ConditionKeep in dry place away from light and heat. Keep out of the reach of children...
Tk.80.00/=
Napa 500/65 mg EXTRA, 1 strip
Napa 500/65 mg EXTRA, 1 stripWhat Napa® Extra is and what it is used for?Napa® Extra (Paracetamol) is a fast and powerful analgesic with marked antipyretic property.It is recommended for the treatment of most painful and febrile conditions, such as headache, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu.Before you take Napa® ExtraCare is advised in the administration of Napa® to patients with renal or hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.Excessive intake of caffeine (e.g. coffee, tea and some canned drinks) should be avoided while taking this product.Seek advice from your doctor if you are pregnant or breastfeeding.Do not-exceed the stated dosetake other paracetamol-containing products concurrentlyConsult your doctor-if symptoms persistif your headaches become persistentHow to take Napa® ExtraAdults: 1-2 tablets 3-4 times dailyChildren: Not recommended for children under 12 years.Possible side effectsSide effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.When the recommended paracetamol-caffeine dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects such as insomnia, restlessness, anxiety, irritability, headaches, gastrointestinal disturbances and palpitations.How to store Napa® ExtraStore in a cool and dry place, away from light. Keep out of the reach and sight of children. Napa Extra Prescribing Information..
Tk.30.00/=
Nipro Gold Tablet, 1 strip
Nipro Gold Tablet, 1 stripDescription:Nipro Gold is a film coated tablet, which combines 32 high potency vitamins and minerals. This preparation maintains a healthy body and active life-style.CompositionEach film coated tablet contains Vitamin A 5000 IU, Vitamin C 60 mg, Vitamin D 400 IU, Vitamin E 30 IU, Vitamin K 25 mcg, Vitamin B1 (Thiamine) 1.5 mg, Vitamin B2 (Riboflavin) 1.7 mg, Vitamin B3 (Niacin) 20 mg, Vitamin B6 (Pyridoxine) 2 mg, Folic acid 400 mcg, Biotin 30 mcg, Pantothenate 10 mg, Calcium 162 mg, Iron 18 mg, Phosphorous 109 mg, Iodine 150 mcg, Magnesium 100 mg, Zinc 15 mg, Selenium 20 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 75 mcg, Chloride 72 mg, Potassium 80 mg, Boron 150 mcg, Nickel 5 mcg, Silicon 2 mg, Tin 10 mcg, Vanadium 10 mcg, Lutein 250 mcg and Cyanocobalamin 6 mcg.IndicationNipro Gold is indicated for the prevention and treatment of vitamins & minerals deficiencies. As a complete daily nutritional supplement, it is also indicated to meet the increased demand for vitamins and minerals in the conditions like physical and emotional stress, chronic diseases, infection illness, osteoporosis, injuries or wound, surgery, poor digestion, old age, pregnancy and lactation, poor appetite, excess dieting, exposure to environmental pollution, heavy exercise etc.Dosage & AdministrationOne tablet daily or as recommended by the physician.ContraindicationThis product is contraindicated in patients with known hypersensitivity to any of the ingredients.PrecautionLong term intake of high level of vitamin A (excluding that sourced from beta carotene) may increase the risk of osteoporosis in postmenopausal women.Side EffectsGenerally, this preparation is well tolerated. Diarrhorea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. Vitamin C and vitamin E may cause diarrhoea and other gastrointestinal disturbances.Drug InteractionNo drug interactions have been reported.Pregnancy & LactationRecommended by the consultation with physicianStorage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.120.00/=
Pansos 40 mg Tablet, 1 strip
Pansos 40 mg Tablet, 1 stripDescription:Pansos (Pantoprazole) is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the H+/K+ATPase enzyme system at the surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the H+/K+ATPase results in a duration of acid antisecretory effect that persists longer than 24 hours.IndicationPansos (Pantoprazole) is indicated where suppression of acid secretion has therapeutic benefit ; i.e1. Peptic ulcer diseases2. Gastroesophageal reflux diseases3. Ulcer, induced by non-steroidal anti-inflammatory drugs (NSAIDs)4. Eradication of Helicobacter pylori (in combination with antibiotics)5. Zollinger-Ellison SyndromeDosage & AdministrationBenign gastric ulcer : 40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed.Gastro-esophageal reflux disease : 20-40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed; maintenance dose is 20 mg daily, which may be increased to 40 mg daily.Duodenal ulcer : 40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed.Duodenal ulcer associated with Helicobacter pylori : Pantoprazole is recommended at a dose of 40 mg twice daily in association with antimicrobial agents as detailed below : Amoxycillin 1 g and Clarithromycin 500 mg both twice daily for one week, or Clarithromycin 250 mg and Metronidazole 400 mg both twice daily for one week.Prophylaxis of NSAID-associated gastric or duodenal ulcer : 20 mg daily for those require long-term NSAID treatment.Zollinger-Ellison Syndrome : Initially 80 mg once daily adjusted according to response (elderly max. 40 mg daily); daily doses above 80 mg given in 2 divided doses.ContraindicationPantoprazole is contraindicated in patients with known hypersensitivity to any of the components of the formulation.PrecautionPatients should be cautioned that Pantoprazole tablet should not be split, chewed or crushed. Long-term therapy of Pantoprazole may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis related disorders.Side EffectsPantoprazole is well tolerated in both short-term and long-term treatment. Headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia.Drug InteractionNo significant drug interactions have been observed in clinical studies.Pregnancy & LactationUS FDA Pregnancy Category of Pantoprazole is B. There are, however, no adequate and well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pantoprazole has been shown to be excreted in human milk. So, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.50.20/=
Prokinet 10 mg Tablet, 1 strip
Prokinet 10 mg Tablet, 1 stripDescription:Prokinet(Domperidone) is a dopamine receptor antagonist. It gives gastroprokinetic action by blocking dopamine receptors located in the chemoreceptor trigger zone (CTZ) and stomach. Due to its weak penetration across the blood-brain barrier, it has almost no effect on the dopaminergic receptors in the brain, therefore excluding psychotropic and neurologic side effects.IndicationIt is used in the following indications:1. Stimulation of gut motility in non-ulcer dyspepsia, gastro-esophageal reflux disease, reflux esophagitis, diabetic gastroparesis & functional dyspepsia.2. Speeding barium transit in follow through radiological studies.3. Prevention and symptomatic relief of acute nausea and vomiting due to cytotoxic therapy, anti-parkinsonism therapy, radio therapy or migraine.Dosage & AdministrationAdults : 10 - 20 mg every 4 - 8 hours daily.Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily. For acute nausea and vomiting, maximum period of treatment is 12 weeks. It should be taken 15 - 30 minutes before a meal.ContraindicationIt is contraindicated in patients with known hypersensitivity to Domperidone or any components of the preparation. Domperidone should not be used whenever gastro-intestinal stimulation might be dangerous (i.e., gastro-intestinal hemorrhage, mechanical obstruction or perforation). It is also contraindicated in prolactinoma.PrecautionIt should be used with absolute caution in case of children because there may be increased risk of extra-pyramidal reactions. Since Domperidone is highly metabolized in liver, it should be used with caution in patient with hepatic impairment.Side EffectsIt may produce hyperprolactinemia (1.3%). This may result in galactorrhea, breast enlargement & soreness and reduced libido. Dry mouth (1.9%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with Domperidone. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies.Drug InteractionThe action of Domperidone on gastro-intestinal function may be antagonized by antimuscarinics and opoid analgesics. Care should be exercised when Domperidone is administered in combination with MAO (monoamine oxidase) inhibitors.Pregnancy & LactationThe safety of use of Domperidone has not been proven duing pregnancy; it is therefore not recommended during pregnancy. Animal studies have not demonstrated teratogenic effects on the fetus. Domperidone may precipitate galactorrhea and improve post-natal lactation. It is secreted in breast milk in very small quantities which is insufficient to be considered harmful.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.20.20/=
Rupatid 10 Tab, 1 strip
Rupatid 10 Tab, 1 stripDescription:Rupatadine is a long-acting, non-sedative antagonist of histamine H1-receptors. It also, antagonizes the platelet-activating factor (PAF). Both histamine and PAF causes bronchoconstriction and lead to an increase in the vascular permeability, acting as a mediator in the inflammatory process. This double mechanism of action gives Rupatadine a major clinical efficacy regarding agents that show an isolated antihistamine action. Rupatadine possesses other anti-allergic properties such as the inhibition of the degranulation of mast cells induced by immunological and non-immunological stimuli, and inhibition of the release of cytokines, particularly of the TNFa in human mast cells and monocytes.IndicationRupatadine is indicated for the symptomatic treatment of allergic rhinitis and urticaria.Dosage & AdministrationAdults and adolescents (above 12 years)- The recommended dosage is 10 mg (one tablet) once daily, with or without food.ContraindicationHypersensitivity to Rupatadine or to any of the excipients.PrecautionAdministration of a dose of 10 mg daily of Rupatadine has not shown significant effects on the function of the central nervous system as seen in specific studies done for psychomotor function. Nevetheless, the patient should take precaution in driving or managing machines. The administration of rupatadine with grape fruit juice is not recommended.Side EffectsThe most common undesirable effects occurs somnolence, headache and fatigue. Other common undesirable effects include dizziness, asthenia and increase appetite.Drug InteractionCYP3A4 inhibitors like Erythromycin & Ketoconazole inhibits both the presystemic and systemic metabolism of Rupatadine. Due to this potential interaction, it is not recommended to use Rupatadine in combination with Ketoconazole, macrolides or any other inhibitors of CYP3A4. Co administration of Rupatadine and CNS depressants or alcohol may increase CNS depressant effect.Pregnancy & LactationPregnancy & Lactation: There is no clinical data available on the exposure of Rupatadine during pregnancy. Pregnant women should therefore not use Rupatadine, unless the potential benefit outweighs the potential risk for the infant. No information is available, whether Rupatadine is excreted in the mothers milk. Therefore, it should not be used during lactation, unless the potential benefits for the mother justify the potential risk to the infant.Elderly: Rupatadine should be used with caution in elderly. No information is available that indicates the requirement of any dose adjustment in this population.Children: Neither the safety nor the efficacy of Rupatadine has been established in patients less than 12 years of age.Patients with renal or hepatic insufficiency: Use of Rupatadine is not recommended in patients with renal or hepatic insufficiency. As no relevant clinical data is available.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children..
Tk.100.00/=
Starcal D Forte Tab, 1 strip
Starcal D Forte Tab, 1 stripDescription:Starcal D is the preparation of Calcium Carbonate and Vitamin D3 (Cholecalciferol). Calcium is necessary for many normal functions of our body, especially bone formation and maintenance. Vitamin D3 helps for the absorption & reabsorption of Calcium. Vitamin D3 also stimulates bone formation. Clinical studies showed that Calcium and Vitamin D3 all together helps in bone growth, and in prevention of osteoporosis & bone fracture.IndicationThis combination is used for treatment of osteoporosis, osteomalacia, rickets, tetany and in parathyroid disease. Calcium supplements are often used to ensure adequate dietary intake in conditions such as pregnancy & lactation, osteogenesis and tooth formation (adjunct with definite treatment) and therapy with anti-seizure medications. It is also used as routine supplement and phosphate binder in chronic renal failure.Dosage & Administration2 tablets daily or 1 tablet twice daily. It is best taken with or just after a meal to improve absorption.ContraindicationIt is contraindicated in case of hypercalcaemia, hyperthyroidism, renal calculi & nephrolithiasis and Zollinger-Ellison Syndrome.PrecautionIf there is any pre-existing heart disease or kidney disease, precautions should be taken.Side EffectsIt is generally well tolerated. If there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. Constipation may occur.Drug InteractionIt has possible interaction with calcium, aluminium or magnesium containing antacids & other calcium supplements, calcitriol & other vitamin D3 supplements; digoxin, tetracycline, doxycycline, minocycline or oxytetracycline.OverdoseSymptoms of overdosage may include nausea and vomiting, severe drowsiness, dry mouth, loss of appetite, metallic taste, stomach cramps, diarrhea, headache, constipation.Pregnancy & LactationThis combination should be used as directed by physician during pregnancy or while breast-feeding.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.120.30/=
Starcal D Tab, 1 strip
Starcal D Tab, 1 stripDescription:Starcal D is the preparation of Calcium Carbonate and Vitamin D3 (Cholecalciferol). Calcium is necessary for many normal functions of our body, especially bone formation and maintenance. Vitamin D3 helps for the absorption & reabsorption of Calcium. Vitamin D3 also stimulates bone formation. Clinical studies showed that Calcium and Vitamin D3 all together helps in bone growth, and in prevention of osteoporosis & bone fracture.IndicationThis combination is used for treatment of osteoporosis, osteomalacia, rickets, tetany and in parathyroid disease. Calcium supplements are often used to ensure adequate dietary intake in conditions such as pregnancy & lactation, osteogenesis and tooth formation (adjunct with definite treatment) and therapy with anti-seizure medications. It is also used as routine supplement and phosphate binder in chronic renal failure.Dosage & Administration2 tablets daily or 1 tablet twice daily. It is best taken with or just after a meal to improve absorption.ContraindicationIt is contraindicated in case of hypercalcaemia, hyperthyroidism, renal calculi & nephrolithiasis and Zollinger-Ellison Syndrome.PrecautionIf there is any pre-existing heart disease or kidney disease, precautions should be taken.Side EffectsIt is generally well tolerated. If there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. Constipation may occur.Drug InteractionIt has possible interaction with calcium, aluminium or magnesium containing antacids & other calcium supplements, calcitriol & other vitamin D3 supplements; digoxin, tetracycline, doxycycline, minocycline or oxytetracycline.OverdoseSymptoms of overdosage may include nausea and vomiting, severe drowsiness, dry mouth, loss of appetite, metallic taste, stomach cramps, diarrhea, headache, constipation.Pregnancy & LactationThis combination should be used as directed by physician during pregnancy or while breast-feeding.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.105.00/=
Tamino Plus 500 mg+65 mg Tablet, 1 strip
Tamino Plus 500 mg+65 mg Tablet, 1 stripDescription:Tamino Plus, is a combination of Paracetamol and Caffeine. Paracetamol has analgesic and antipyretic properties with weak anti-inflammatory activity. Caffeine is an alkaloid which is a theophylline-like xanthine derivative. By intermolecular association with Paracetamol, Caffeine increases the solubility and transmembrane permeation of Paracetamol. In addition, Caffeine increases the pain threshold and tolerance of pain. Caffeine has also an intrinsic power to raise vessel tone in the brain, which provides another benefit to treat migraine and headache.IndicationIt is indicated for the relief of fever, migraine and headache, common cold and flu, sore throat, earache, toothache, backache, rheumatic and muscular pain, neuralgia and menstrual pain.Dosage & AdministrationIt is used for adults and adolescents over 12 years of age as 1-2 tablets in every 4-6 hours as needed. Maximum dose is 8 tablets in 24 hours. It is not recommended for children under 12 years of age.ContraindicationTamino Plus is contraindicated in patients with known hypersensitivity to Paracetamol, Caffeine or any other components of it.PrecautionIt should be used with caution in severe liver or kidney damage. Do not take other Paracetamol containing medications at the same time. Avoid drinking too much coffee or tea when taking this tablet.Side EffectsIn recommended doses, it is usually free from side effects. However, skin reactions such as urticaria have been reported rarely.Drug InteractionIt may interact with anticoagulant agents on prothrombin time. The liver effects of it may be increased by the concomitant use of alcohol certain drugs which enhance the metabolism of Paracetamol in the liver (i.e. barbiturates, tricyclic antidepressants).Pregnancy & LactationAlthough there is epidemiological evidence of the safety of Paracetamol in pregnancy and lactation, medical advice should be sought before using this product.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.15.10/=
V3N Tab, 1 Strip
V3N Tab, 1 StripDescription:V3N is a combined preparation of Vitamin B1 (Thiamine Mononitrate), Vitamin B6 (Pyridoxine Hydrochloride) and Vitamin B12 (Cyanocobalamin). These vitamins play an essential role as co-enzyme in the metabolism of nervous system. supports the regeneration of nerve fibers and myelin sheath by activation of the nerve cell metabolism and the natural repair mechanism.IndicationChronic pains like sciatica, lumbago, trigeminal neuralgia, facial paralysis, optic neuritis as well as neuropathy & cardiac complications. Besides these, this combination may be used in the deficiency of these vitamins.Dosage & Administration1 to 3 tablets per day or as directed by the physician.ContraindicationIt should not be used in patients with known hypersensitivity to Thiamine, Cobalt or any other component of these preparations.PrecautionIt should be avoided in case of hypersensitivity to Thiamine, Cobalt or any other component of these preparations. Cyanocobalamin should not be given before a diagnosis has been fully established because of the masking symptoms of subacute degeneration of the spinal cord.Side EffectsVery rarely hypersensitive reaction and sensitivity disturbance may occur.Drug InteractionVitamin B6 (Pyridoxine Hydrochloride) reduces therapeutic effect of Levodopa but it does not occur if a dopa decarboxylase inhibitor is also given. Neomycin, Chloramphenicol, Aminosalisylic acid & H2 receptor antagonist may reduce Vitamin B12 absorption.Pregnancy & LactationNo risks have become known associated with the use of during pregnancy at the recommended dosage. Vitamin B1, B6 & B12 are secreted into the breast milk but risks of overdose for the infant are not known.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.80.00/=
Visnil 50 mg Tablet, 1 strip
Visnil 50 mg Tablet, 1 stripDescription:Visnil (Tiemonium Methylsulphate) is an antispasmodic drug that reduces muscles spasm of the intestine, biliary system, bladder and uterus.IndicationVisnil (Tiemonium Methylsulphate) is used in symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system. It is also indicated for the treatment of spasm and pain in urological and gynaecological diseases.Dosage & AdministrationAdult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses.Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses.ContraindicationIt should not be used in urethroprostatic disorder involving a risk of urine retension. It is contraindicated in patient with having risk of angle closure glaucoma.PrecautionCaution should be taken during treatment of patients with disorders of the prostate. Caution should also be taken in case of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal & hepatic insufficiency. The risks of visual disturbances can make it dangerous to drive or use machines.Side EffectsTiemonium Methylsulphate may have the risk of hypotension & tachycardia in certain individuals.Pregnancy & LactationThe results of animal studies of Tiemonium Methylsulphate did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.Storage ConditionKeep in dry place and away from light and heat. Keep out of the reach of children...
Tk.40.10/=
A-Cal 250 mg Tablet, 1 strip
A-Cal 250 mg Tablet, 1 stripDESCRIPTIONCalcium is an essential body electrolyte. It is involved in the maintenance of normal muscle and nerve function, cardiac function and is essential to blood coagulation.Calcium Carbonate has three main actions: it supplements dietary calcium, neutralizes gastric acid in peptic ulcer disease and sequesters phosphorous in the intestine to reduce total body phosphate accumulation in chronic renal failure. Calcium requirement varies with age and is relatively greater in childhood, pregnancy and lactation dueto an increased demand, in old age due to impaired absorption, and as phosphate binder in patients with renal failure. Absorption depends on previous intake of calcium, other nutrients, pregnancy, lactation, overall calcium balance and availability of vitamin D.COMPOSITIONA-CAL 250 chewable : Each chewable tablet contains Calcium Carbonate BP 0.625 g equivalent to 250 mg elemental Calcium. A-CAL 250 : Each film-coated tablet contains Calcium Carbonate BP 0.625 g equivalent to 250 mg elemental Calcium. A-CAL 500 : Each film-coated tablet contains Calcium Carbonate BP 1.25 g equivalent to 500 mg elemental Calcium.INDICATIONSIn calcium deficiency states : Treatment of calcium deficiency states including osteomalacia, rickets and mal-absorption syndromes affecting the upper gastrointestinal tract.As therapeutic supplementation : During times when intake may be inadequate, particularly those associated with the increased demand of childhood, old age, pregnancy and lactation. As a phosphate binder : As effective phosphate binder given by mouth to reduce phosphate absorption from the gut in patient with hyperphosphataemia, chronic renal failure in order to prevent the development of renal osteo-dystrophy. Osteoporosis : An adjunct to conventional therapy in the arrest or slowing down of bone demineralisation in osteoporosis or when other effective treatment is contraindicated. As an antacid : Usually in association with other antacids, especially magnesium containing antacids.DOSAGE AND ADMINISTRATIONA-Cal 250 :Adults : 2 tablets daily.Children : 1-2 tablets daily.A-Cal 500 : 1 tablet daily.OR AS DIRECTED BY THE PHYSICIAN.SIDE EFFECTSMild gastrointestinal disturbances may occur rarely (e.g. nausea, abdominal pain, constipation, flatulence and eructation etc.)CONTRAINDICATIONSCalcium Carbonate is contraindicated in hypercalcemia and hyperparathyroidism, hypercalcemia and nephrolithiasis, Zollinger Ellison Syndrome etc.PRECAUTIONSShould be used with caution in patients with impaired renal function, a history of stone formation should also be recommended to increase their fluid intake. High doses of vitamin D should be avoided during calcium therapy unless specially indicated. In case of hypercalciuria the dosage should be reduced or treatment stopped.USE IN PREGNANCY AND LACTATIONCalcium supplements have been in wide use for many years without apparent ill consequence.DRUG INTERACTIONSCalcium Carbonate and other antacids may interfere with the absorption of concomitantly administered tetracycline preparations or ciprofloxacin. This can be minimized by giving Calcium Carbonate and the other medication 2 to 3 hours apart.SUPPLYA-CAL 250 chewable : Each box contains 3 X 10 tablets in blisterstrips.A-CAL 250 : Each box contains 10 X 10 tablets in blister strips.A-CAL 500 : Each box contains 10 X 10 tablets in blister strips...
Tk.15.00/=
A-Mectin 12 mg Tablet, 1 strip
A-Mectin 12 mg Tablet, 1 stripCompositionA-Mectin 6 mg Tablet: Each tablet contains Ivermectin BP 6 mg.A-Mectin 12 mg Tablet: Each tablet contains Ivermectin BP 12 mg.PharmacologyIvermectin is a member of the avermectin class of broadspectrum antiparasitic agents. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. It may also impair normal intrauterine development of parasites and may inhibit their release from the uteri of gravid female parasites.IndicationIvermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin is indicated for the treatment of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Onchocerciasis. Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.ContraindicationsIt is contraindicated in patients who are hypersensitive to any component of this product.Warning & precautionMicrofilaricidal drugs, such as diethylcarbamazine citrate, might cause cutaneous and/or systemic reactions of varying severity and ophthalmological reactions in patients with onchocerciasis. Stop taking Ivermectin and seek emergency medical attention if you experience symptoms of arare but serious allergic reaction including swelling of the lips, tongue or face.Side EffectsIt has been reported after treatment with Ivermectin like abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis.Use in pregnancy & LactationPregnancy Category C. It is excreted in human milk in low concentrations. Treatment of mothers who intend to breast feed should only be undertaken when the risk of delayed treatment to the mother outweighs the possible risk to the newborn.Use in Children & AdolescentsSafety and effectiveness in pediatric patients weighing less than 15 kg have not been established.Drug InteractionsAs with other microfilaricidal drugs, there was an increase in the microfilariae count in the anterior chamber of the eye at day 3 after treatment in some patientsOverdoseIt is not known..PackingA-Mectin 6: Each box contains 1x10’sA-Mectin 12: Each box contains 1x10’s..
Tk.300.00/=
A-Mectin 6 mg Tablet, 1 strip
A-Mectin 6 mg Tablet, 1 stripCompositionA-Mectin 6 mg Tablet: Each tablet contains Ivermectin BP 6 mg.A-Mectin 12 mg Tablet: Each tablet contains Ivermectin BP 12 mg.PharmacologyIvermectin is a member of the avermectin class of broadspectrum antiparasitic agents. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. It may also impair normal intrauterine development of parasites and may inhibit their release from the uteri of gravid female parasites.IndicationIvermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin is indicated for the treatment of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Onchocerciasis. Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.ContraindicationsIt is contraindicated in patients who are hypersensitive to any component of this product.Warning & precautionMicrofilaricidal drugs, such as diethylcarbamazine citrate, might cause cutaneous and/or systemic reactions of varying severity and ophthalmological reactions in patients with onchocerciasis. Stop taking Ivermectin and seek emergency medical attention if you experience symptoms of arare but serious allergic reaction including swelling of the lips, tongue or face.Side EffectsIt has been reported after treatment with Ivermectin like abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis.Use in pregnancy & LactationPregnancy Category C. It is excreted in human milk in low concentrations. Treatment of mothers who intend to breast feed should only be undertaken when the risk of delayed treatment to the mother outweighs the possible risk to the newborn.Use in Children & AdolescentsSafety and effectiveness in pediatric patients weighing less than 15 kg have not been established.Drug InteractionsAs with other microfilaricidal drugs, there was an increase in the microfilariae count in the anterior chamber of the eye at day 3 after treatment in some patientsOverdoseIt is not known..PackingA-Mectin 6: Each box contains 1x10’sA-Mectin 12: Each box contains 1x10’s..
Tk.150.00/=
Adarbi 80 mg Tablet, 1 Strip
Adarbi 80 mg Tablet, 1 StripDescription:Adarbi (Azilsartan Medoxomil), a prodrug, is hydrolyzed to Azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.IndicationAdarbi (Azilsartan Medoxomil) is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarction. Adarbi (Azilsartan Medoxomil) may be used either alone or in combination with other antihypertensive agents.Dosage & AdministrationThe recommended dose in adults is 80 mg taken orally once daily. Consider a Starting dose of 40 mg for patients who are treated with high doses of diuretics. If blood pressure is not controlled with Adarbi alone, additional blood pressure reduction can be ahieved by taking Edarbi with other antihypertensive agents.ContraindicationIt is contraindicated to co-administer Aliskiren with Azilsartan in patients with Diabetes.PrecautionUse of Azilsartan Medoxomil during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. In patients who are intravascularly volume-depleted (e.g., those treated with high-dose diuretics), symptomatic hypotension may occur. Changes in renal function including renal failure has been reported in renal impaired patient.Side EffectsThe most common adverse reaction in adults is diarrhea. The other side effects are nausea, asthenia, fatigue, muscle spasm, dizziness and cough.Drug InteractionNo drug interactions have been observed in studies of Azilsartan Medoxomil or Azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone and warfarin. The antihypertensive effect of Azilsartan may be attenuated by the non-steroidal anti-inflammatory drugs including selective COX-2 inhibitors. Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors or aliskiren is associated with increased risks of hypotension, hyperkalemia and changes in renal function.Storage Conditionkeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.220.00/=
Apresin Tablet, 1 strip
Apresin Tablet, 1 stripFluphenazine Hydrochloride BP and Nortriptyline Hydrochloride combination is an effective preparation for the patients suffering from anxiety or depression or both. Fluphenazine is a tranquilizer of the phenothiazine type. Nortriptyline is a tricyclic antidepressant having less sedative action. This combination helps to restore functional ability without developing any drug dependence. Apresin® is indicated for the treatment of mild to moderate mixed anxiety/depression, emotional disturbance, sleep disorder and also in gastric problems.Helps to relieve mixed anxiety Depressive DisordersAids patients to lead a normal lifeOffer better safety to the patients..
Tk.10.50/=
Arth-A 250/200 mg Tablet, 1 strip
Arth-A 250/200 mg Tablet, 1 stripDESCRIPTIONARTH-A tablet is a balanced combination of two leading natural supplements of healthy cartilage Glucosamine and Chondroitin. Glucosamine is a naturally occurring amino sugar of cartilage that provides the basic raw material needed by the body to manufacture joint cartilage. And Chondroitin is another naturally occurring mucopolysaccharide of cartilage that stimulates cartilage production, inhibits cartilage destroying enzymes, draws fluid to the cells and helps lubricate the joints. They work synergistically together to help stimulate the regeneration and prevent the destruction of connective tissues (e.g., cartilage, bone, tendon etc.).COMPOSITIONARTH-A tablet : Each film-coated tablet contains Glucosamine Hydrochloride USP 250 mg and Chondroitin Sulfate USP 200 mg.INDICATIONSTreatment of osteoarthritis of knee, hip, spine, hand and other locations. As a dietary supplement to prevent osteoarthritis.DOSAGE AND ADMINISTRATION1-2 tablets 3 times daily. Obese individuals may need higher doses, based on body weight.OR AS DIRECTED BY THE PHYSICIAN.SIDE-EFFECTSBoth Glucosamine Hydrochloride and Chondroitin Sulfate are virtually nontoxic. Side effects are rare and are limited to stomach upset, nausea or diarrhea. These usually disappear when the tablet is taken with meals.CONTRAINDICATIONSThere are no known contraindications for Glucosamine and Chondroitin. But proven hypersensitivity to Glucosamine and Chondroitin is a contraindication.PRECAUTIONSDiabetics are advised to monitor blood glucose levels regularly while taking Glucosamine. No special studies were found for patients with renal and/or hepatic insufficiency. The toxicological and pharmacokinetic profile of the product does not indicate limitations for these patients. However, administration to these patients with severe hepatic or renal insufficiency should be under appropriate medical supervision.USE IN PREGNANCY & LACTATIONWomen who are pregnant or who could become pregnant should take it with speical caution.DRUG INTERACTIONSThere have been no reports of significant drug interactions of Glucosamine with antibiotics, antidepressants, antihypertensives, nitrates, antiarrythmics, anxiolytic, hypoglycemic agents, antisecretives and antiasthmatics. But in case of Chondroitin there is a chance of drug interaction with blood-thinning medications (e.g., warfarin, heparin).SUPPLYARTH-A tablet : Each box contains 12 X 4 tablets in Alu-Alu blister strips...
Tk.80.70/=
Arth-A TS 750/600 mg Tablet, 1 strip
Arth-A TS 750/600 mg Tablet, 1 stripGlucosamine Sulfate 750 mg & Chondroitin Sulfate 600 mg TabletCompositionEach film-coated tablet contains Glucosamine Sulfate Potassium Chloride USP eq. to Glucosamine Sulfate 750 mg and Chondroitin Sulfate Sodium USP eq. to Chondroitin Sulfate 600 mg.PharmacologyArth-A® TS tablet is a balanced combination of two leading natural supplements of healthy cartilage Glucosamine and Chondroitin. Glucosamine is a naturally occurring amino sugar of cartilage that provides the basic raw material needed the body to manufacture joint cartilage. Chondroitin is another naturally occurring mucopolysaccharide of cartilage that stimulates cartilage production, inhibits cartilage destroying enzymes, draws fluid to the cells and helps lubricate the joints. They work synergistically together to help stimulate the production and regeneration of connective tissues (e.g. cartilage, bone tendon, skin, mucous membrane, blood vessels etc.).IndicationsIndicated for the treatment of osteoarthritis of knee, hip, spine, hand, and other locations as a dietary supplement. It is also beneficial in rheumatoid arthritis, sport injuries, migraine, different skin problems (e.g. psoriasis), vascular complications (e.g. atherosclerosis), kidney stones and inflammatory bowel disease (e.g. ulcerative colitis, leaky gut syndrome).Dosage and AdministrationRoute of Administration : Orally. 1 tablet two times daily. Or as directed by the physician.ContraindicationsThere are no known contraindications for Glucosamine and Chondroitin. But proven hypersensitivity to Glucosamine and Chondroitin is a contraindication.Warning & PrecautionsDiabetics patients are advised to monitor blood glucose levels regularly while taking Glucosamine. No. special studies were formed in patients with renal and /or hepatic insufficiency. The toxicological and pharmacokinetic profile of the product does not indicate limitations for these patients. However administration to these patients with severe hepatic or renal insufficiency should be under appropriate medical supervision.Side-EffectsCommon side effects: Both Glucosamine and Chondroitin Sulfates are virtually nontoxic. Rare side effects: Side effects are rare and are limited to stomach upset, nausea, constipation or diarrhoea. These usually disappear when the tablet is taken with meals.Use in pregnancy & LactationWomen who are pregnant or who could become pregnant should not be supplemented with Glucosamine and Chondroitin. Glucosamine and Chondroitin has not been studied enough to determine their effects on a developing fetus. No studies have evaluated the use of glucosamine and Chondroitin during pregnancy or lactation. Glucosamine and Chondroitin should be taken with caution and medical advice during pregnancy and lactation.Use in Children & AdolescentsSafety and efficacy in children below 12 years of age have not been established.Drug InteractionsWith Medicine : There have been no reports of significant drug interactions of Glucosamine with antibiotic/anti-depressants/ anti-hypertensives/ nitrates/ anti-arrhythmic/anxiolytic/ hypoglycemic agents /anti-secretives. But in case of Chondroitin there is a chance of drug interaction with blood-thinning medications (e.g. warfarin, heparin). With food & others : No interaction with food & others.OverdoseDiarrhoea may be occurred.StorageKeep out of the reach of children. Store below 300 C & in dry place, protected from light.PackingEach box contains 3X10 tablets in alu-alu blisters...
Tk.160.00/=
Betabis-A 2.5/5 mg Tablet, 1 strip
Betabis-A 2.5/5 mg Tablet, 1 stripCOMPOSITIONBetabisTM-A 2.5/5: Each film-coated tablet contains Bisoprolol Fumarate USP 2.5 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.PHARMACOLOGYBetabisTM-A is a fixed-dose combination of Bisoprolol and Amlodipine. Amlodipine is a dihydropyridine calcium antagonist that inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscles. It has greater affinity towards vascular smooth muscles than on cardiac muscles. Amlodipine is a peripheral vasodilator that acts directly on vascular smooth muscles to cause a reduction in peripheral vascular resistance and thus reduces blood pressure. Bisoprolol is a cardioselective beta (β1) blocker without intrinsic sympathomimetic activity in its therapeutic dosage range. This combination allows increasing the antihypertensive and anti-anginal efficacy by complementary mechanism of actions of the two active compounds..INDICATIONBetabisTM-A (Bisoprolol & Amlodipine combination) is indicated for the treatment of hypertension and angina pectoris. It is also indicated for the treatment of hypertension as substitution therapy in patients adequately controlled or not controlled with the individual products given concurrently at the same doses level as in the combination, but as separate tablets. It is also indicated for those patients with angina pectoris and hypertension as co-existing diseases.DOSAGE & ADMINISTRATIONRoute of Administration: BetabisTM-A needs to be taken orally. The usual starting dose of BetabisTM-A is one tablet daily with or without food. If the desired therapeutic effect cannot be achieved, the dose may be increased. The dose however should be individualized.OR AS DIRECTED BY THE PHYSICIAN.CONTRAINDICATIONThis combination is usually well-tolerated. But it is contraindicated for patients with cardiogenic shock, high grade aortic stenosis, sinoatrial block, symptomatic bradycardia and symptomatic hypotension.WARNINGS AND PRECAUTIONSBronchospasm: The combination should be used with caution in patients with airway obstruction.For Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment. In case of severe renal impairment (creatinine clearance <20 mL/min), the daily dose must not exceed 10 mg. For Hepatic Impairment: In case of severe hepatic impairment, the daily dose must not exceed 10 mg.SIDE EFFECTSCommon side effects: Headache, drowsiness, dizziness, somnolence, palpitations, flushing, feeling of coldness or numbness, nausea, vomiting, diarrhea, constipation, abdominal pain, edema and fatigue. Rare side effects: Bradycardia, dyspnea, syncope, insomnia, mood changes, depression, sleep disorder , tremor, hypotension, drymouth, alopecia, chest pain, dyspepsia, allergic reactions, night mare, hallucination, confusion etc.USE IN PREGNANCY AND LACTATIONIn Pregnancy: There are no adequate and well-controlled studies in pregnant women. This combination should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In Lactation: This combination should be stopped during breast feeding.USE IN CHILDREN & GERIATRIC PATIENTSIn Children: Safety and effectiveness in paediatric patients have not been established. In Geriatric Patilents: No dosage adjustment is required. But caution is advised when the dose is increased.DRUG INTERACTIONWith Medicines:CYP3A4 Inhibitors: Concomitant use of Amlodipine with strong or moderate CYP3A4 Inhibitors (e. g. Protease Inhibitors, Verapamil or Diltiazem) can be expected to increase the plasma concentrations of Amlodipine.Insulin & Oral Antidiabetic Drugs: In combination of Bisoprolol with these drugs, intensification of blood sugar lowering effect may occur.Centrally Acting Antihypertensive Drugs : Concomitant use of these drugs (e.g. Clonidine, Methyldopa, Moxonidine, Rilmenidine) with Bisoprolol may lead to reductionof heart rate and cardiac output, as well as to vasodilation. Anesthetic Agents: In combination with Bisoprolol, the reflex tachycardia may be attenuated and the risk of hypotension may be increased. Cardiac glycosides: Concomitant use of these drugs (e.g. Digitalis) with Bisoprolol may lead to a reduction of heart rate or an increase of atrio-ventricular conduction time. With foods & others: No food interaction with this combination.OVERDOSEThe most common signs expected with overdose of Bisoprolol & Amlodipine combination are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency, hypoglycemia, peripheral vasodilation and possibly reflex tachycardia.STORAGEStore below 300 C and in dry place, protected from light. Keep all medicines out of reach of children.PACKINGBetabisTM-A 2.5/5 : Each box contains 3X10 tablets in Alu-Alu blister strips..
Tk.60.00/=
Bilista 20 mg Tablet, 1 strip
Bilista 20 mg Tablet, 1 stripIndication:Bilista™ is indicated for the symptomatic treatment of• Allergic rhino-conjunctivitis (seasonal and perennial)• Urticaria.Bilastine is also used to relieve the symptoms of hay fever (sneezing, itchy, runny, blocked-nose and red and watery eyes).Dosage & Administration:• Adults and adolescents (12 years of age and over): 20 mg (1 tablet) once daily.• Children under 12 years: The safety and efficacy in children under 12 years have not been established yet.• Elderly: No dosage adjustments are required for elderly patients.The maximum recommended daily dose of Bilastine is 20 mg which should be taken one hour before or two hours after intake of food.Preparation:Bilista™ 20 Tablet: Each box contains 20 tablets in blister pack...
Tk.150.00/=
Bisocam 2.5/5 mg Tablet, 1 strip
Bisocam 2.5/5 mg Tablet, 1 stripIndication:Hypertension (High Blood Pressure)Dosage & Administration:The recommended daily dose is one tablet with or without food.Preparation:BisocamTM: Each box contain 30’s tablet in Alu- Alu blister pack...
Tk.60.00/=
Briva 25 mg Tablet, 1 strip
Briva 25 mg Tablet, 1 stripBriva 10 mg/ml Oral Solution 50 ml bottle CompositionBriva 25 Tablet: Each film-coated tablet contains Brivaracetam INN 25 mg.Briva 50 Tablet: Each film-coated tablet contains Brivaracetam INN 50 mg.Briva Oral Solution: Each ml contains Brivaracetam INN 10 mg.PharmacologyThe precise mechanism by which Brivaracetam exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.Brivaracetam exhibits linear and time-independent pharmacokinetics at the approved doses. Brivaracetam is highly permeable and is rapidly and almost completely absorbed after oral administration. Brivaracetam is rapidly and evenly distributed in most tissues. More than 95% of the dose, including metabolites, is excreted in the urine.Indications Epilepsy Partial-Onset of Seizure including Focal Impaired Awareness or Complex Partial Seizures Focal Aware or Simple Partial Seizure Secondarily Generalized Seizures or Bilateral Tonic Clonic SeizureDosage and Administration:Route of Administration: OrallyMonotherapy or Adjunctive TherapyThe recommended dosage for adults and pediatric patients 4 years of age and older is included in below table. In pediatric patients (> 4 years to < 16 years of age), the recommended dosing regimen is dependent upon body weight. When initiating treatment, gradual dose escalation is not required. Dosage should be adjusted based on clinical response and tolerability.Geriatric UseDose selection for an elderly patient should be judicious, usually starting at the low end of the dosing range.Renal ImpairmentDose adjustment of Brivaracetam is not required for patients with impaired renal function. Use of Brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis.Hepatic ImpairmentFor all stages of hepatic impairment, the recommended starting dosage of Brivaracetam is 25 mg twice daily (50 mg per day) and the recommended maximum dosage is 75 mg twice daily (150 mg per day).OR AS DIRECTED BY THE PHYSICIANContraindications Contraindicated in patient with hypersensitivity to Brivaracetam or any of the inactive ingredients in Brivaracetam.Warnings and PrecautionsLike other antiepileptic drugs, Brivaracetam may cause suicidal thoughts or actions in a very small number of people. Patients should be restricted from driving or operating machinery until they have gained sufficient experience on Brivaracetam. Brivaracetam should be gradually withdrawn. If Bronchospasm and Angioedema develops, should seek immediate medical care.Side EffectsAdults:Common Side Effects: Sedation, Dizziness, Drowsiness, Fatigue and Nausea or Vomiting etc. Rare Side Effects: Cerebellar coordination and balance disturbances, Mood swings, Anxiety, Hallucination, Delusion, Irritability, Constipation, Bronchospasm, Decreased Neutrophils, Decreased White Blood Cells, Giant Hives etc. Pediatric Patients: Most common adverse reactions are similar to those seen in adult patients.Pregnancy and LactationPregnancy: Pregnancy Category of Brivaracetam is C. There is no adequate and well-controlled studies in pregnant women.Brivaracetam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: No data are available regarding the presence of Brivaracetam in human milk, the effects on the breastfed infant or the effects of the drug on milk production.Use in Children and AdolescentSafety and effectiveness in pediatric patients below the age of 4 years have not been established.Drug InteractionsWith Medicine: Rifampin: Because of decreased concentrations, increasing Brivaracetam dosage in patients on concomitant Rifampin is recommended.Carbamazepine: Consider reducing Carbamazepine dosage in patients on concomitant Brivaracetam. Phenytoin: Phenytoin levels should be monitored in patients on concomitant Brivaracetam.With Food and Others: Food does not affect the extent of Brivaracetam absorption. Brivaracetam can be taken with or without food. Use of alcohol during Brivaracetam therapy is not recommended.OverdoseThere is limited clinical experience with Brivaracetam overdose in humans. Vertigo, balance disorder, fatigue, nausea, diplopia, anxiety, and bradycardia were reported as adverse reaction ofBrivaracetam overdose.StorageStore below 300 C temperature and in a dry place, protected from light. Keep all medicines out of reach of children. Do not freeze the oral solution.PackingBriva 25 Tablet: Each Box contains 1X10 Tablets in Alu-Alu blister.Briva 50 Tablet: Each Box contains 1X10 Tablets in Alu-Alu blister.Briva Oral Solution: Each box contains a bottle containing 50 ml oral solution and a measuring cup...
Tk.400.00/=
Camlotel 5/40 mg Tablet, 1 strip
Camlotel 5/40 mg Tablet, 1 stripIndication:HypertensionDosage & Administration:The usual starting dose of Amlodipine & Telmisartan is 5/40 mg (Camlotel™ 5/40) once daily. Patients requiring larger blood pressure reductions may be started with 5/80 mg once daily.Preparation:Camlotel™ 5/40: Each box contains 30 tablets in blister pack...
Tk.125.00/=
Carceva 75 mg Tablet, 1 Strip
Carceva 75 mg Tablet, 1 StripDescription:Clopidogrel is a prodrug. It inhibits platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses. Repeated doses of 75 mg per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7.CompositionEach film coated tablet contains Clopidogrel Hydrogen Sulfate BP equivalent to Clopidogrel 75 mg.IndicationAcute Coronary Syndrome (ACS):It is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)]. It is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI).Recent MI, recent Stroke, or established Peripheral Arterial Disease:In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke it is indicated to reduce the rate of MI and stroke.Dosage & AdministrationAcute Coronary Syndrome:In patients who need an antiplatelet effect within hours, initiate clopidogrel with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily. Initiating it without a loading dose will delay establishment of an antiplatelet effect by several days.Recent MI, Recent Stroke, or Established Peripheral Arterial Disease:75 mg once daily orally without a loading dose.It is given orally with or without food.ContraindicationClopidogrel is contraindicated in the following conditions:* Hypersensitivity to the drug substance or any component of the product.* Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.PrecautionAs it is a prodrug, so metabolism to its active metabolite is impaired by genetic variations in CYP2C19 (poor metabolizer) and by the drugs that inhibit CYP2C19 such as Omeprazole and Esomeprazole. Concomitant use with these drugs and in CYP2C19 poor metaboliser may reduce the antiplatelet activity of Clopidogrel.* As it inhibits platelet aggregation for the lifetime of the platelet (7-10 days), risk of bleeding may increase. To restore hemostasis, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.* Discontinuation of Clopidogrel increases the risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. Resume Clopidogrel as soon as hemostasis is achieved.* Thrombotic Thrombocytopenic Purpura (TTP) has been reported that requires urgent treatment including plasmapheresis (plasma exchange).*Hypersensitivity including rash, angioedema or hematologic reaction has been reported in patients receiving clopidogrel or history of hypersensitivity to other thienopyridines.Side EffectsClopidogrel is generally well tolerated drug.Common side effects: Bleeding, Diarrhoea, gastrointestinal discomfort, haemorrhage, Skin reactions.Rare side effects: Acquired haemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders.Drug Interaction* NSAIDs, warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding* CYP2C19 inhibitors (omeprazole or esomeprazole): Avoid concomitant use of omeprazole or esomeprazole.* Repaglinide (CYP2C8 substrates): Avoid concomitant use of Clopidogrel with Repaglinide as it increases plasma concentrations of RepaglinideOverdoseOverdose following clopidogrel administration may lead to bleeding complications. Based on biological plausibility, platelet transfusion may restore clotting ability.Pregnancy & LactationThere are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. It is unknown whether clopidogrel is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.USE IN SPECIFIC POPULATIONSafety and effectiveness in pediatric populations have not been established. No dosage adjustment is necessary in elderly patients.Storage ConditionKeep below 30oC temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children...
Tk.100.00/=
Clocard 75 mg Tablet, 1 Strip
Clocard 75 mg Tablet, 1 StripIndicationsClopidogrel is indicated for the reduction of atherosclerotic events like myocardial infarction, stroke and vascular death in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease.PharmacologyClopidogrel is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel also inhibits platelet aggregation induced by agonists other than ADP by blocking the amplification of platelet activation by released A.P. Clopidogrel does not inhibit phosphodiesterase activity.InteractionConcomitant use of Heparin, Warfarin and NSAIDs with Clopidogrel should be undertaken with caution. Clopidogrel potentiate the effect of Aspirin on collagen-induced platelet aggregation. The safety of chronic concomitant administration of Aspirin and Clopidogrel has not been established.ContraindicationsClopidogrel is contraindicated in patients with a hypersensitivity to the drug substance or any component of the product, and those with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.Side EffectsGenerally Clopidogrel is well tolerated. However, a few common side effects i.e. Influenza-like symptoms, headache, upper respiratory tract infection, dizziness, muscle and back pain, and rash may occur.Pregnancy & LactationPregnancy: There are no adequate and well-controlled studies of Clopidogrel in pregnant women. However, Clopidogrel should be used during pregnancy only if clearly needed.Lactation: Clopidogrel is not recommended for use while breast-feeding. It is not known for sure whether Clopidogrel is excreted in breast milk, although it is suspected that it is.PrecautionsAs with other anti-platelet agents, Clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions. Clopidogrel should be discontinued 7 days prior to surgery. Clopidogrel should be used with caution in hepatically impaired patients who may have bleeding diatheses.Overdose EffectsSymptoms: Prolonged bleeding time and subsequent bleeding complications.Management: May restore clotting ability with platelet transfusion...
Tk.110.00/=
Cozycol 800 mg Tablet, 1 strip
Cozycol 800 mg Tablet, 1 stripIndication:CozycolTM 800 (Mesalamine 800 mg) delayed release tablet is used to treat- Mild to moderately active Ulcerative Colitis (UC)- Maintenance of remission of Ulcerative Colitis (UC)- Treatment & maintenance of remission of Crohn’s Disease (CD)Mesalamine works locally at colonic mucosa of the Gut. It reduces inflammation by inducing activation and expression of PPAR-γ and inhibiting inflammatory mediators (IL-1, TNF, NFkB & Leukotriene, arachidonic acid metabolites, free oxygen radical. It increases immunosuppression by inhibiting antibody production.It also reduces UC associated Colorectal Cancer (CRC) by inducing anti-tumorigenic effect and apoptosis of the inflamed cells.Dosage & Administration:Adults:Acute disease: 3-6 delayed release tablets (2400-4800 mg) daily in divided doses for 6 (six) weeks.Maintenance therapy: The recommended dosage is 3 delayed release tablets (2400 mg) daily in divided doses.Maintenance of remission of Crohn’s disease: 3 delayed release tablets (2400 mg) daily in divided doses.Preparation:CozycolTM 800: Each box contains 30 tablets in blister pack...
Tk.120.00/=
D-Balance 2000 IU Capsule, 1 strip
D-Balance 2000 IU Capsule, 1 stripIndication:For the prevention & treatment of Vitamin D3 & associated diseases like Osteomalacia, Rickets, Fractures, Preeclampsia, Eclampsia, during pregnancy & for the management of Cardiovascular & Diabetic profile.Dosage & Administration:Treatment guideline for 200,000 IU Oral/IM injectable solution:Curative measures:DiseaseDosages (up to normalization of vitamin D level)Rickets1 ampoule every 2 weeks for one month then 1 ampoule for every 4 monthsOsteoporosis1 ampoule every 2 weeks for 3 monthsOsteomalacia1 ampoule every 2 weeks for 3 monthsVitamin D deficiency1 ampoule can be repeated 1 to 6 months laterPreventive measures:DiseaseDosages (up to normalization of vitamin D level)Pregnacy1/2 ampoule at 6th or 7th monthDuring Breast feeding1/2 ampoule for every 6 monthsChildren up to 5 years1 ampoule for every 6 monthsAdolescent1 ampoule for every 6 monthsElderly1/2 ampoule for every 3 monthsTreatment guideline for Capsule:2000 IU LicapOnce/day (when vitamin D level is sufficient : ≥30 ng/ml or ≥ 75 nmol/L)20000 IU LicapOnce/week for 6-10 weeks for vitamin D insufficient patients(when serum vitamin D level is 20-30 ng/mL or 50-75 nmol/L )40000 IU LicapOnce/week for 6-10 weeks for vitamin D deficient patients(when serum vitamin D level is 12-19 ng/mL or 25-50 nmol/L )50000 IU LicapOnce/week for 6-10 weeks for severe vitamin D deficient patients(when serum vitamin D level is <12 ng/mL or <25 nmol/L)Dosing of capsule for Vitamin D deficiency in Children:Vitamin D deficiency (12-18 years)20000 IU, once every 2 weeks for 6 weeksPrevention of Vitamin D deficiency (12-18 years)20000 IU, once every 6 weeksPreparation:D-balanceTM 2000 Licap: Each Box containing 30 Licap in 30’s Alu-Alu blister pack.D-balanceTM 20000 Licap: Each Box containing 10 Licap in 10’s Alu-Alu blister pack.D-balanceTM 40000 Licap: Each Box containing 10 Licap in 10's Alu-Alu blister pack.D-balanceTM 50000 Licap: Each Box containing 10 Licap in 10's Alu-Alu blister pack.D-balanceTM 50000 Licap: Each Box containing 10 Licap in 10's Alu-Alu blister pack.D-balanceTM 200,000 IU Oral/IM Injectable Solution : Each box contains 1 ampoule in blister pack...
Tk.40.00/=
Defungi 50 mg Capsule, 1 Strip
Defungi 50 mg Capsule, 1 StripDescription:Defungi (Fluconazole) is a triazole antifungal agent. It is a potent inhibitor of fungal cytochrome P-450 dependent enzymes. Cytochrome P-450 enzyme system is essential component of fungal cell membrane which is responsible for the synthesis of ergosterol.IndicationIt is indicated for the treatment of vaginal candidiasis, oropharyngeal & esophageal candidiasis and cryptococcal meningitis. It is also effective for the treatment of urinary tract infection caused by candida, peritonitis and systemic candida infections (including candidemia, disseminated candidiasis and pneumonia).Dosage & AdministrationAdult:Vaginal candidiasis: 150 mg as a single dose. Oropharyngeal candidiasis: 200 mg on the first day, followed by 100 mg once daily. Clinical evidence of this infection generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse. Esophageal candidiasis: 200 mg on the first day, followed by 100 mg once daily. Doses up to 400 mg/day may be used. Patients should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms. Systemic candida infections: Optimal therapeutic dosage and duration of therapy have not been established. Sometimes, doses of up to 400 mg daily have been used. Urinary tract infections caused by candida and peritonitis: 50-200 mg daily have been used. Cryptococcal meningitis: 400 mg on the first day, followed by 200 mg once daily. Prophylaxis in patients undergoing bone marrow transplantation: 400 mg once daily.Child:Doses of 3-6 mg/kg daily have been used. Doses up to 12 mg/kg is recommended.ContraindicationFluconazole should not be used in patients with known hypersensitivity to Fluconazole or to related triazole compounds.PrecautionFluconazole should be administered with caution to patients having proarrhythmic conditions.Side EffectsFluconazole is well tolerated. Most common side effects of using Fluconazole includes nausea, vomiting, abdominal pain, diarrhoea, headache and skin rash.Drug InteractionConcomitant use of cyclosporin or phenytoin with Fluconazole increases the plasma level of cyclosporin or phenytoin. Concomitant use of Fluconazole & warfarin prolongs the prothrombin time. Rifampicin level is decreased when used with Fluconazole.Pregnancy & LactationUS FDA Pregnancy category of Fluconazole is C. So, Fluconazole should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children..
Tk.80.60/=
Diaryl 3 mg Tablet, 1 strip
Diaryl 3 mg Tablet, 1 strip1. What Diaryl is and what it is used for?Diaryl® is a preperation of Glimepiride BP, which belongs to sulphonylurea class. The primary mechanism of action of Glimepiride is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Glimepiride. Administration of Glimepiride can lead to increase sensitivity of peripheral tissues to insulin. After oral administration Glimepiride is completely (100%) absorbed from GI tract. When Glimepiride is given with meals, the mean Tmax is slightly increased (12%) and the mean Cmax and AUC are slightly decreased. Glimepiride is completely metabolized by oxidative biotransformation after oral dose.When 14 C-Glimepiride is given orally, approximately 60% of the total radioactivity is recovered in the urine in 7 days and 80-90% of the metabolites are recovered in the urine. Non-insulin dependent (type-II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction. Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.2. Before you take DiarylContraindicationGlimepiride is not suitable for the treatment of insulin dependent (type-I) diabetes mellitus, (e.g. for the treatment of diabetes with a history of ketoacidosis), or of diabetic precoma or coma. Glimepiride must not be used in patients hypersensitive to Glimepiride, other sulphonylureas and other sulphonamides.PrecautionIn the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates careful monitoring. If such risk is present it may be necessary to adjust the dosage of Glimepiride. Hypoglycaemia can almost always be promptly controlled by immediate intake of carbohydrates (glucose or sugar).Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.Drug InteractionPotentiation of the blood-sugar-lowering effect may occur with insulin and other oral anti-diabetics, ACE inhibitors, allopurinol, anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, fluoxetine, MAO inhibitors, miconazole, para-aminosalicylic acid, pentoxifylline (high dose parenteral), phenylbutazone, oxyphenbutazone, quinolones, salicylates, sulphonamides, tetracyclines, beta blockers.Weakening of the blood-sugar-lowering effect may occur with acetazolamide, barbiturates3. How to take Diaryl?Glimepiride tablet must be swallowed without chewing and with sufficient amount of liquid (approximately 1/2 glass).4. Possible side effectsHypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.5. How to store Diaryl?Store in a dry place, at temperature between 15° C and 30° C, away from light...
Tk.120.10/=
Diazid 80 mg Tablet, 1 strip
Diazid 80 mg Tablet, 1 stripDescription:Diazid 80 (Gliclazide) is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic ß-cells by facilitating Ca2+ transport across the ß-cell membranes and decreases hepatic glucose outputIndicationDiazid is indicated for the treatment of non insulin dependent diabetes mellitus (NIDDM) of patients who require oral antidiabetic treatment.Dosage & AdministrationOral route: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal. For children Gliclazide is not used because it is contraindicated in juvenile- onset diabetes.ContraindicationGliclazide should not be used in -* Juvenile-onset (type - I) diabetes* Diabetes associated with Ketosis* Diabetic patients undergoing surgery, after severe injury or during infection* Patients having hypersensitivity for sulfonylurea group of drugs* Pregnant women and breast-feeding mother* Hepatic insufficiencyPrecautionGliclazide should be used carefully in patients with hepatic impairment. If there is definite hepatic disease then gliclazide should not be used. Gliclazide can be used safely in patients with renal insufficiency as it is extensively metabolized. Gliclazide has less sudden hypoglycaemic episode than other sulfonylurea group of drugs.Side EffectsThere may be hypoglycaemia in concurrent conditions such as hepatic and renal disease, malnutrition, alcohol intoxication. Sometimes headache, gastrointestinal upsets, nausea, dizziness, skin reactions including rash, pruritus, erythema may occur.Drug InteractionThe hypoglycaemic effects of Gliclazide may be increased by Aspirin, NSAIDs, Phenylbutazone, Clofibrate, Sulfonamides, Cimetidine, Imidazole antifungal agents and Monoamine Oxidase inhibitors. The hypoglycaemic effect of Gliclazide some times may be reduced by Rifampin, Barbiturates, Phenytoin, Thiazide diuretics, Diazoxide, Glucocorticoids, Estrogens, Sympathomimectic drugs and occasionally Alcohol.Pregnancy & LactationGliclazide is contraindicated in pregnant women. It should not be used in breast feeding mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.60.20/=
Dulox 20 mg Tablet, 1 strip
Dulox 20 mg Tablet, 1 stripDESCRIPTIONDulox (Duloxetine hydrochloride) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) that is indicated for the treatment of major depressive disorder (MDD) and for the management of neuropathic pain associated with diabetic peripheral neuropathy(DPN). The exact mechanism of the antidepressant and central pain inhibitory actions of Duloxetine is unknown, it is thought to be related to the potentiation of the serotonergic and noradrenergic central nervous system activity. In addition to inhibiting the reuptake of serotonin and norepinephrine, Duloxetine also inhibits the reuptake of dopamine, although to a lesser degree.COMPOSITIONDulox 20 : Each enteric coated tablet contains Duloxetine Hydrochloride INN 22.45 mg equivalent to Duloxetine 20 mg.Dulox 30 : Each enteric coated tablet contains Duloxetine Hydrochloride INN 33.67 mg equivalent to Duloxetine 30 mg.INDICATIONSDulox is indicated for:● Major Depressive Disorder (MDD)● Generalized Anxiety Disorder (GAD)● Diabetic Peripheral Neuropathic Pain (DPNP)● Fibromyalgia (FM)DOSAGE AND ADMINISTRATIONDulox should generally be administered once daily without regard to meals. Dulox should be swallowed whole and should not be chewed.Indication Recommended DoseMajor Depressive Disorder● Generalized Anxiety Disorder 60 mg/day (once daily)● Diabetic Peripheral 60 mg/day (once daily)● Neuropathic Pain● Fibromyalgia 60 mg/day (once daily)Some patients may benefit from starting at 30 mg once daily. Discontinuing Dulox: A gradual dose reduction is recommended.OR AS DIRECTED BY THE PHYSICIAN.CONTRAINDICATIONSDulox (Duloxetine hydrochloride) is contraindicated in patients with known hypersensitivity to Duloxetine or any of the inactive ingredients. Concomitant use of Dulox (Duloxetine hydrochloride) with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated.SIDE EFFECTSThe most common observed side effects in Dulox (Duloxetine hydrochloride) treated major depressive disorder (MDD) patients are nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. In case of Dulox (Duloxetine hydrochloride) treated diabetic peripheral neuropathy (DPN) patients the most commonly observed side effects are nausea, somnolence, dizziness, dry mouth, constipation, decreased appetite, hyperhidrosis and asthenia.PRECAUTIONSDulox (Duloxetine hydrochloride) treatment is associated with mean increases in blood pressure. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment.Dulox (Duloxetine hydrochloride) should be prescribed with care in patients with a history of seizure disorder and mania. Dulox (Duloxetine hydrochloride) is associated with an increase risk of mydriasis; therefore it should be used cautiously in patients with controlled narrow- angle glaucoma.USE IN PREGNANCYThere are no adequate and well-controlled studies in pregnant women; therefore, Dulox (Duloxetine hydrochloride) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.USE IN LABOR AND DELIVERYThe effect of Duloxetine on labor and delivery in humans is unknown.Dulox (Duloxetine hydrochloride) should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.USE IN LACTATIONIt is unknown whether or not Duloxetine and/or its metabolites are excreted into human milk, but nursing while on Dulox (Duloxetine hydrochloride) is not recommended.USE IN CHILDRENSafety and effectiveness in the pediatric population have not been established. Anyone considering the use of Dulox (Duloxetine hydrochloride) in a child or adolescent must balance the potential risks with the clinical need.USE IN ELDERLYNo overall differences in safety and effectiveness are observed between elder and younger.DRUG INTERACTIONSBoth CYP1A2 and CYP2D6 are responsible for Duloxetine metabolism. Concomitant use of Duloxetine with Fluvoxamine, an inhibitor ofCYP1A2, results in approximately a 6- fold increase in AUC and about a 2.5- fold increase in Cmax of Duloxetine. Some quinolone antibiotics would be expected to have similar effects and these combinationsshould be avoided. Concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of DuloxetineOVERDOSAGEThere is limited clinical experience with Duloxetine overdose in humans. In clinical trials, no cases of fatal acute overdose of Duloxetine have been reported.SUPPLYDulox 20 : Each box contains 1 x 10's tablets in blister strip.Dulox 30 : Each box contains 1 x 10's tablets in blister strip...
Tk.70.40/=